

**Ligase Enzymes Market by Type (DNA, RNA), Source (Viral, Bacterial, Eukaryotic), Grade (RUO, GMP, Diagnostic), Molecular Biology Workflow (Cloning, Sequencing, Synthetic Biology), Application (Research, Diagnostic, Therapeutic) - Global Forecast 2030**

Market Report | 2025-09-12 | 311 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

The ligase enzymes market is expected to reach USD 0.36 billion in 2030 from USD 0.26 billion in 2025, at a CAGR of 6.8% during the forecast period. The growth of the ligase enzymes market is driven by the rising adoption of genomics and next-generation sequencing (NGS), the expansion of molecular diagnostics and personalized medicine, and the increasing use of synthetic biology. Ligases play a central role in NGS workflows by enabling adapter ligation & library construction, making them indispensable in large-scale genomics projects and precision medicine initiatives. Its growing application in molecular diagnostics and precision medicine is also expected to fuel the market growth.

<https://www.marketsandmarkets.com/Images/ligase-enzymes-market-Overview.webp>

By grade, the GMP-grade ligase enzymes segment is projected to register the highest CAGR during the forecast period. By grade, the ligase enzymes market is segmented into Research Use Only (RUO), GMP-grade, and diagnostic-grade ligase enzymes. The GMP-grade ligase enzymes segment is expected to grow at the highest CAGR during the forecast period. The growth is supported by the rising demand for GMP-grade ligase enzymes in therapeutic manufacturing, gene therapy, and clinical applications where compliance with stringent quality and safety standards is essential. The increasing investments in cell & gene therapies, biopharmaceutical production, and diagnostic assay development are also expected to fuel the market growth. By source, the viral sources segment accounted for the largest share of the market in 2024. Based on the source, the ligase enzymes market is segmented into viral, bacterial, archaeal, and eukaryotic sources. In 2024, the

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

viral ligases segment accounted for the largest market share owing to its high adoption in applications such as molecular biology workflows, particularly in cloning, DNA repair studies, and next-generation sequencing (NGS) library preparation. Viral ligases, such as T4 DNA ligase, are considered industry standards because of their high efficiency in catalyzing the joining of DNA fragments, making them indispensable in research & industrial biotechnology.

By region, the Asia Pacific market is projected to grow at the highest CAGR during the forecast period.

By region, the market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is projected to grow at the highest CAGR during the forecast period owing to the increasing investments in genomics research, expansion in biotechnology & pharmaceutical industries, and the rising focus on precision medicine. China, Japan, South Korea, and India are significantly scaling up their R&D capabilities through government funding, public-private partnerships, and international collaborations, creating strong demand for molecular biology tools, including ligase enzymes. The growing adoption of next-generation sequencing (NGS), synthetic biology, and molecular diagnostics for cancer, infectious diseases, and rare genetic disorders further supports market expansion.

The primary interviews conducted for this report can be categorized as follows:

-□By Company Type: Tier 1- 44%, Tier 2- 32%, and Tier 3- 24%

-□By Designation: (Managers)- 45%, (CXOs, Directors)- 30%, and (Executives)- 25%

-□By Region: North America- 40%, Europe- 25%, Asia Pacific- 20%, and the Rest of the World- 15%

Promega Corporation (US), New England Biolabs (UK), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), and Takara Bio Inc. (Japan) are some of the key players in the ligase enzymes market.

The study includes an in-depth competitive analysis of these key players in the ligase enzymes market and their company profiles, recent developments, and key market strategies.

#### Research Coverage:

This research report categorizes the ligase enzymes market by type (DNA, RNA, other ligases), by source (viral, bacterial, archaeal, eukaryotic), by grade (RUO, GMP, diagnostic), by molecular biology workflow (cloning & mutagenesis, synthetic biology, sequencing, nucleic acid amplification), by application (research, diagnostic, therapeutic development & manufacturing, other applications), by end user (academic & research institutes, pharmaceutical and biotechnology companies, hospital & diagnostic laboratories, medical device companies), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The report provides in-depth information on significant factors influencing the growth of the ligase enzymes market, including drivers, trends, challenges, and opportunities. A thorough analysis of leading industry players has been undertaken to provide insights into their business profiles, products, key strategies, collaborations, partnerships, and agreements. Additionally, the report encompasses recent developments such as new product launches and acquisitions within the ligase enzyme market.

#### Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the ligase enzyme market and its subsegments. It will also help stakeholders better understand the competitive landscape & gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

-□Analysis of key drivers (rising genomics & NGS activities, growth of molecular diagnostics & personalized medicine, and increasing use in synthetic biology), restraints (dependency on research funding), opportunities (development of thermostable/performance-engineered ligases, development of lyophilized/shelf-stable ligases for point-of-care testing and low-resource markets), and challenges (batch-to-batch variability & quality control, growing adoption of ligase independent cloning) influencing the growth of the market.

-□Product Development/Innovation: Detailed insights on newly launched products of the ligase enzyme market

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the ligase enzyme market
- Competitive Assessment: In-depth assessment of market share, growth strategies of leading players like New England Biolabs (UK), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), and Promega Corporation (US), among others, in the ligase enzymes market.

**Table of Contents:**

- 1□INTRODUCTION□30
- 1.1□STUDY OBJECTIVES□30
- 1.2□MARKET DEFINITION□30
- 1.3□STUDY SCOPE□31
- 1.3.1□MARKET SEGMENTATION & REGIONAL SCOPE□31
- 1.3.2□INCLUSIONS & EXCLUSIONS□32
- 1.3.3□YEARS CONSIDERED□33
- 1.3.4□CURRENCY CONSIDERED□33
- 1.4□STAKEHOLDERS□33
- 2□RESEARCH METHODOLOGY□34
- 2.1□RESEARCH DATA□34
- 2.1.1□SECONDARY DATA□35
- 2.1.2□PRIMARY DATA□35
- 2.2□MARKET ESTIMATION METHODOLOGY□37
- 2.2.1□GLOBAL MARKET SIZE ESTIMATION, 2024□37
- 2.2.2□SEGMENTAL MARKET ASSESSMENT□40
- 2.3□MARKET GROWTH RATE PROJECTIONS□42
- 2.4□DATA TRIANGULATION□44
- 2.5□RESEARCH ASSUMPTIONS□45
- 2.6□RESEARCH LIMITATIONS□46
- 2.7□RISK ASSESSMENT□46
- 3□EXECUTIVE SUMMARY□47
- 3.1□KEY INSIGHTS & MARKET HIGHLIGHTS□47
- 3.2□STRATEGIC IMPERATIVES FOR STAKEHOLDERS IN LIGASE ENZYMES MARKET□52
- 3.3□DISRUPTIVE TRENDS SHAPING LIGASE ENZYMES MARKET□53
- 3.4□HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS□53
- 4□PREMIUM INSIGHTS□54
- 4.1□GLOBAL LIGASE ENZYMES MARKET SNAPSHOT□54
- 4.2□NORTH AMERICA: LIGASE ENZYMES MARKET, BY TYPE AND COUNTRY (2024)□55
- 4.3□LIGASE ENZYMES MARKET, BY TYPE (2024)□55
- 4.4□LIGASE ENZYMES MARKET, BY END USER (2024)□56
- 4.5□LIGASE ENZYMES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES□56
- 4.6□UNMET NEEDS & WHITE SPACES□57
- 4.7□STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES□57
- 4.7.1□STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES□57
- 4.8□EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS□58
- 4.9□SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES□59
- 5□MARKET OVERVIEW□60
- 5.1□INTRODUCTION□60

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.2	MARKET DYNAMICS	60
5.2.1	DRIVERS	61
5.2.1.1	Rising genomics & NGS activity	61
5.2.1.2	Growth of molecular diagnostics & personalized medicine	62
5.2.1.3	Growing use in synthetic biology	62
5.2.2	RESTRAINTS	63
5.2.2.1	Dependence on research funding	63
5.2.3	OPPORTUNITIES	63
5.2.3.1	Development of thermostable/performance-engineered ligases	63
5.2.3.2	Development of lyophilized/shelf-stable ligases for point-of-care testing (POCT) and low-resource markets	64
5.2.4	CHALLENGES	64
5.2.4.1	Batch-to-batch variability & quality control	64
5.2.4.2	Growth in adoption of sequence and ligase-independent cloning (SLIC)	65
6	INDUSTRY TRENDS	66
6.1	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	66
6.1.1	SHIFT TOWARD HIGH-THROUGHPUT & AUTOMATED WORKFLOWS	66
6.1.2	EXPANSION OF LIGASE APPLICATIONS IN RAPID & POINT-OF-CARE TESTING	66
6.2	VALUE CHAIN ANALYSIS	67
6.3	ECOSYSTEM ANALYSIS	69
6.4	TECHNOLOGY ANALYSIS	70
6.4.1	KEY TECHNOLOGIES	70
6.4.1.1	Precision fermentation	70
6.4.1.2	Enzyme engineering & protein design	71
6.4.2	COMPLEMENTARY TECHNOLOGIES	71
6.4.2.1	Chromatography & purification technologies	71
6.4.2.2	Cryopreservation & stabilization technologies	71
6.5	PATENT ANALYSIS	71
6.5.1	METHODOLOGY	71
6.5.2	PATENTS APPLIED & GRANTED, 2014-2024	72
6.6	TRADE ANALYSIS	74
6.6.1	IMPORT DATA (HS CODE 350790)	74
6.6.2	EXPORT DATA (HS CODE 350790)	76
6.7	PORTER'S FIVE FORCES ANALYSIS	77
6.7.1	THREAT OF NEW ENTRANTS	78
6.7.2	THREAT OF SUBSTITUTES	78
6.7.3	BARGAINING POWER OF SUPPLIERS	78
6.7.4	BARGAINING POWER OF BUYERS	78
6.7.5	INTENSITY OF COMPETITIVE RIVALRY	79
6.8	TARIFF & REGULATORY LANDSCAPE	79
6.8.1	TARIFF DATA (HS CODE 350790)	79
6.8.2	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	80
6.8.3	REGULATORY FRAMEWORK	82
6.9	PRICING ANALYSIS	84
6.9.1	AVERAGE SELLING PRICE TREND OF LIGASE ENZYMES, BY KEY PLAYER, 2022-2024	84

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.9.2	AVERAGE SELLING PRICE OF LIGASE ENZYMES, BY REGION, 2024	85
6.10	KEY CONFERENCES & EVENTS, 2025-2026	86
6.11	KEY STAKEHOLDERS & BUYING CRITERIA	87
6.11.1	KEY STAKEHOLDERS IN BUYING PROCESS	87
6.11.2	ROLE OF STAKEHOLDERS IN BUYING PROCESS	88
6.11.3	BUYING CRITERIA	89
6.12	INVESTMENT & FUNDING SCENARIO	90
6.13	IMPACT OF AI/GENERATIVE AI ON LIGASE ENZYMES MARKET	90
6.13.1	AI USE CASES	91
6.13.2	KEY COMPANIES IMPLEMENTING AI	92
6.13.3	FUTURE OF AI	92
6.14	IMPACT OF 2025 US TARIFFS ON LIGASE ENZYMES MARKET	92
6.14.1	INTRODUCTION	92
6.14.2	KEY TARIFF RATES	93
6.14.3	PRICE IMPACT ANALYSIS	93
6.14.4	IMPACT ON COUNTRY/REGION	93
6.14.4.1	US	93
6.14.4.2	Europe	94
6.14.4.3	Asia Pacific	94
6.14.5	END-USE INDUSTRY IMPACT	95
6.14.5.1	Pharmaceutical & biotechnology companies	95
6.14.5.2	Medical device companies	95
6.14.5.3	Academic & research institutes	95
6.14.5.4	Hospitals & diagnostic laboratories	95
7	LIGASE ENZYMES MARKET, BY TYPE	96
7.1	INTRODUCTION	97
7.2	DNA LIGASES	97
7.2.1	HIGH ADOPTION OF DNA LIGASES TO SUPPORT MARKET GROWTH	97
7.3	RNA LIGASES	100
7.3.1	GROWING ADOPTION OF RNA SEQUENCING AND DEVELOPMENT IN RNA THERAPEUTICS TO DRIVE MARKET GROWTH	100
7.4	OTHER LIGASES	103
8	LIGASE ENZYMES MARKET, BY SOURCE	106
8.1	INTRODUCTION	107
8.2	VIRAL LIGASES	107
8.2.1	WIDE COMMERCIAL USE OF VIRAL LIGASES BY COMPANIES TO SUPPORT MARKET GROWTH	107
8.3	BACTERIAL LIGASES	110
8.3.1	HIGH SPECIFICITY AND COMPATIBILITY OF BACTERIAL LIGASES WITH CERTAIN APPLICATIONS TO SUPPORT MARKET GROWTH	110
8.4	EUKARYOTIC LIGASES	113
8.4.1	EXPANDING ROLE OF EUKARYOTIC LIGASES IN DNA REPAIR ASSAYS AND CRISPR-MEDIATED GENOME EDITING TO BOOST MARKET	113
8.5	ARCHAEAL LIGASES	116
8.5.1	RISING DEMAND FOR HIGH-TEMPERATURE LIGATION METHODS IN PCR CLONING TO FUEL GROWTH	116
9	LIGASE ENZYMES MARKET, BY GRADE	119
9.1	INTRODUCTION	120

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

9.2	RUO-GRADE LIGASES	120
9.2.1	LOW COST OF RUO-GRADE LIGASE ENZYMES TO SUPPORT MARKET GROWTH	120
9.3	GMP-GRADE LIGASES	123
9.3.1	GROWING PIPELINE FOR DNA AND RNA-BASED THERAPEUTICS TO SUPPORT MARKET GROWTH	123
9.4	DIAGNOSTIC-GRADE LIGASES	126
9.4.1	CONTINUOUS PRODUCT INNOVATION TO POSITION DIAGNOSTIC-GRADE LIGASES AS HIGH-OPPORTUNITY GROWTH SEGMENT	126
10	LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW	129
10.1	INTRODUCTION	130
10.2	CLONING & MUTAGENESIS	130
10.2.1	WIDE ADOPTION OF CLONING TECHNIQUES TO SUPPORT MARKET GROWTH	130
10.3	SYNTHETIC BIOLOGY	133
10.3.1	GROWING EXPANSION OF SYNTHETIC BIOLOGY IN HEALTHCARE TO DRIVE MARKET GROWTH	133
10.4	SEQUENCING	136
10.4.1	INCREASING DEMAND FOR LARGE-SCALE GENOME PROJECTS TO BOOST MARKET GROWTH	136
10.5	NUCLEIC ACID AMPLIFICATION	139
10.5.1	GROWING DEMAND FOR RAPID, ACCURATE, AND COST-EFFECTIVE MOLECULAR DIAGNOSTICS TO SUPPORT MARKET GROWTH	139
11	LIGASE ENZYMES MARKET, BY APPLICATION	142
11.1	INTRODUCTION	143
11.2	RESEARCH APPLICATIONS	143
11.2.1	GROWING RESEARCH STUDIES TO SUPPORT MARKET GROWTH	143
11.3	DIAGNOSTIC APPLICATIONS	146
11.3.1	GROWING DEMAND FOR MOLECULAR DIAGNOSTICS AND PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH	146
11.4	THERAPEUTIC DEVELOPMENT & MANUFACTURING	149
11.4.1	GROWING DEMAND FOR GMP-GRADE ENZYMES IN LARGE-SCALE MANUFACTURING TO PROPEL MARKET GROWTH	149
11.5	OTHER APPLICATIONS	152
12	LIGASE ENZYMES MARKET, BY END USER	155
12.1	INTRODUCTION	156
12.2	ACADEMIC & RESEARCH INSTITUTES	156
12.2.1	GROWING RESEARCH STUDIES TO SUPPORT MARKET GROWTH	156
12.3	PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES	159
12.3.1	GROWING DEMAND FOR PERSONALIZED MEDICINE TO BOOST MARKET GROWTH	159
12.4	HOSPITALS & DIAGNOSTIC LABORATORIES	162
12.4.1	GROWING INTEGRATION OF LIGASE-BASED MOLECULAR DIAGNOSTIC TESTS INTO ROUTINE CARE TO SUPPORT MARKET GROWTH	162
12.5	MEDICAL DEVICE COMPANIES	164
12.5.1	GROWING FOCUS ON RAPID, RELIABLE, AND USER-FRIENDLY DIAGNOSTIC DEVICES TO FUEL GROWTH	164
13	LIGASE ENZYMES MARKET, BY REGION	168
13.1	INTRODUCTION	169
13.2	NORTH AMERICA	169
13.2.1	MACROECONOMIC OUTLOOK FOR NORTH AMERICA	173
13.2.2	US	174
13.2.2.1	Increasing R&D investments and funding to drive market	174

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.2.3	CANADA	176
13.2.3.1	Supportive government policies to propel market growth	176
13.3	EUROPE	179
13.3.1	MACROECONOMIC OUTLOOK FOR EUROPE	182
13.3.2	GERMANY	183
13.3.2.1	Strong healthcare infrastructure and government-backed genomics initiatives to support market	183
13.3.3	UK	185
13.3.3.1	Growing adoption of genomics and presence of advanced research infrastructure to drive demand	185
13.3.4	FRANCE	188
13.3.4.1	Growing government funding for R&D to propel market	188
13.3.5	ITALY	190
13.3.5.1	Growing research funding to drive market growth	190
13.3.6	SPAIN	193
13.3.6.1	Increasing number of biotechnology companies to drive demand	193
13.3.7	REST OF EUROPE	195
13.4	ASIA PACIFIC	198
13.4.1	MACROECONOMIC OUTLOOK FOR ASIA PACIFIC	201
13.4.2	CHINA	202
13.4.2.1	Increasing R&D expenditure to support market growth	202
13.4.3	JAPAN	204
13.4.3.1	Advanced biotechnology industry and strong research base to support market growth	204
13.4.4	INDIA	206
13.4.4.1	Growing government support in evolving biotechnology sector to boost market	206
13.4.5	SOUTH KOREA	209
13.4.5.1	Increasing government support to boost market	209
13.4.6	AUSTRALIA	211
13.4.6.1	Growing biotechnology sector to boost demand	211
13.4.7	REST OF ASIA PACIFIC	213
13.5	LATIN AMERICA	216
13.5.1	MACROECONOMIC OUTLOOK FOR LATIN AMERICA	218
13.5.2	BRAZIL	219
13.5.2.1	Rising focus on biotechnology industry to support market	219
13.5.3	MEXICO	221
13.5.3.1	Government support for biopharmaceutical production to drive market	221
13.5.4	REST OF LATIN AMERICA	224
13.6	MIDDLE EAST	226
13.6.1	MACROECONOMIC OUTLOOK IN MIDDLE EAST	229
13.6.2	GCC COUNTRIES	229
13.6.2.1	Saudi Arabia	232
13.6.2.1.1	Increasing investments in genomics to drive market	232
13.6.2.2	United Arab Emirates	234
13.6.2.2.1	Advancements in biopharmaceutical sector to drive demand	234
13.6.2.3	Rest of GCC Countries	237
13.6.3	REST OF MIDDLE EAST	239
13.7	AFRICA	241
13.7.1	GROWING FUNDING FOR SUPPORTING RESEARCH INFRASTRUCTURE TO DRIVE MARKET	241

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.7.2 □ MACROECONOMIC OUTLOOK FOR AFRICA □ 244
- 14 □ COMPETITIVE LANDSCAPE □ 245
- 14.1 □ OVERVIEW □ 245
- 14.2 □ KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021-2025 □ 245
- 14.3 □ REVENUE ANALYSIS, 2020-2024 □ 246
- 14.4 □ MARKET SHARE ANALYSIS, 2024 □ 247
- 14.5 □ COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 □ 250
- 14.5.1 □ STARS □ 250
- 14.5.2 □ EMERGING LEADERS □ 250
- 14.5.3 □ PERVASIVE PLAYERS □ 250
- 14.5.4 □ PARTICIPANTS □ 251
- 14.5.5 □ COMPANY FOOTPRINT: KEY PLAYERS, 2024 □ 252
- 14.5.5.1 □ Company footprint □ 252
- 14.5.5.2 □ Region footprint □ 253
- 14.5.5.3 □ Type footprint □ 254
- 14.5.5.4 □ Source footprint □ 254
- 14.5.5.5 □ Application footprint □ 255
- 14.6 □ COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 □ 256
- 14.6.1 □ PROGRESSIVE COMPANIES □ 256
- 14.6.2 □ RESPONSIVE COMPANIES □ 256
- 14.6.3 □ DYNAMIC COMPANIES □ 256
- 14.6.4 □ STARTING BLOCKS □ 256
- 14.6.5 □ COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 □ 258
- 14.6.5.1 □ Detailed list of key startups/SMEs □ 258
- 14.6.5.2 □ Competitive benchmarking of key startups/SMEs □ 259
- 14.7 □ COMPANY VALUATION & FINANCIAL METRICS □ 260
- 14.7.1 □ FINANCIAL METRICS □ 260
- 14.7.2 □ COMPANY VALUATION □ 260
- 14.8 □ BRAND/PRODUCT COMPARISON □ 261
- 14.8.1 □ BRAND/PRODUCT COMPARATIVE ANALYSIS □ 261
- 14.9 □ COMPETITIVE SCENARIO □ 261
- 14.9.1 □ DEALS □ 261
- 15 □ COMPANY PROFILES □ 262
- 15.1 □ KEY PLAYERS □ 262
- 15.1.1 □ NEW ENGLAND BIOLABS □ 262
- 15.1.1.1 □ Business overview □ 262
- 15.1.1.2 □ Products offered □ 262
- 15.1.1.3 □ MnM view □ 263
- 15.1.1.3.1 □ Key strengths □ 263
- 15.1.1.3.2 □ Strategic choices □ 263
- 15.1.1.3.3 □ Weaknesses & competitive threats □ 263
- 15.1.2 □ THERMO FISHER SCIENTIFIC INC. □ 264
- 15.1.2.1 □ Business overview □ 264
- 15.1.2.2 □ Products offered □ 265
- 15.1.2.3 □ MnM view □ 266
- 15.1.2.3.1 □ Key strengths □ 266
- 15.1.2.3.2 □ Strategic choices □ 266

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.1.2.3.3 Weaknesses & competitive threats 266
- 15.1.3 QIAGEN N.V. 267
  - 15.1.3.1 Business overview 267
  - 15.1.3.2 Products offered 268
  - 15.1.3.3 MnM view 269
    - 15.1.3.3.1 Key strengths 269
    - 15.1.3.3.2 Strategic choices 269
    - 15.1.3.3.3 Weaknesses & competitive threats 269
- 15.1.4 PROMEGA CORPORATION 270
  - 15.1.4.1 Business overview 270
  - 15.1.4.2 Products offered 270
  - 15.1.4.3 MnM view 271
    - 15.1.4.3.1 Key strengths 271
    - 15.1.4.3.2 Strategic choices 271
    - 15.1.4.3.3 Weaknesses & competitive threats 271
- 15.1.5 TAKARA BIO INC. 272
  - 15.1.5.1 Business overview 272
  - 15.1.5.2 Products offered 273
  - 15.1.5.3 MnM view 274
    - 15.1.5.3.1 Key strengths 274
    - 15.1.5.3.2 Strategic choices 274
    - 15.1.5.3.3 Weaknesses & competitive threats 274
- 15.1.6 DANAHER CORPORATION 275
  - 15.1.6.1 Business overview 275
  - 15.1.6.2 Products offered 276
  - 15.1.6.3 MnM view 277
    - 15.1.6.3.1 Key strengths 277
    - 15.1.6.3.2 Strategic choices 277
    - 15.1.6.3.3 Weaknesses & competitive threats 277
- 15.1.7 AGILENT TECHNOLOGIES, INC. 278
  - 15.1.7.1 Business overview 278
  - 15.1.7.2 Products offered 279
- 15.1.8 F. HOFFMANN-LA ROCHE LTD. 280
  - 15.1.8.1 Business overview 280
  - 15.1.8.2 Products offered 281
  - 15.1.8.3 Recent developments 282
    - 15.1.8.3.1 Deals 282
- 15.1.9 MERCK KGAA 283
  - 15.1.9.1 Business overview 283
  - 15.1.9.2 Products offered 284
- ?
- 15.1.10 ARCTICZYMES TECHNOLOGIES 285
  - 15.1.10.1 Business overview 285
  - 15.1.10.2 Products offered 286
- 15.1.11 BIOSYNTH 287
  - 15.1.11.1 Business overview 287
  - 15.1.11.2 Products offered 287

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

15.1.12	HIMEDIA LABORATORIES	288
15.1.12.1	Business overview	288
15.1.12.2	Products offered	288
15.1.13	LGC BIOSEARCH TECHNOLOGIES	289
15.1.13.1	Business overview	289
15.1.13.2	Products offered	289
15.1.14	INSPIRALIS LIMITED	290
15.1.14.1	Business overview	290
15.1.14.2	Products offered	290
15.1.15	BIONEER CORPORATION	291
15.1.15.1	Business overview	291
15.1.15.2	Products offered	291
15.2	OTHER PLAYERS	292
15.2.1	GENO TECHNOLOGY INC.	292
15.2.2	MBR, INC.	292
15.2.3	ABCLONAL, INC.	293
15.2.4	NZYTECH	294
15.2.5	JENA BIOSCIENCE GMBH	295
15.2.6	CREATIVE ENZYMES.	295
15.2.7	ENZYNOMICS CO., LTD.	296
15.2.8	BIOCAT GMBH	297
15.2.9	GENAXXON BIOSCIENCE	298
15.2.10	MERIDIAN BIOSICENCE	299
15.2.11	CANVAX	300
15.2.12	BIOTECHRABBIT	301
15.2.13	MCLAB	302
16	APPENDIX	303
16.1	DISCUSSION GUIDE	303
16.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	307
16.3	CUSTOMIZATION OPTIONS	309
16.4	RELATED REPORTS	309
16.5	AUTHOR DETAILS	310

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Ligase Enzymes Market by Type (DNA, RNA), Source (Viral, Bacterial, Eukaryotic), Grade (RUO, GMP, Diagnostic), Molecular Biology Workflow (Cloning, Sequencing, Synthetic Biology), Application (Research, Diagnostic, Therapeutic) - Global Forecast 2030**

Market Report | 2025-09-12 | 311 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code\*

Country\*

Date

2026-06-09

Signature

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)